Mylan Inc. Receives a New Rating from Top Analyst

By Ryan Adsit

In a report released today, Irina Rivkind Koffler from Mizuho Securities reiterated a Buy rating on Mylan Inc. (NASDAQ: MYL), with a price target of $47. The company’s shares closed yesterday at $37.56.

According to, Koffler is a top 100 analyst with an average return of 17.8% and a 50.9% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Apricus Biosciences Inc, Sucampo Pharmaceuticals, and Pacira Pharmaceuticals.

Currently, the analyst consensus on Mylan Inc. is Moderate Buy and the average price target is $50.75, representing a 35.1% upside.

In a report issued on November 9, Merrill Lynch also reiterated a Buy rating on the stock with a $53 price target.

Based on Mylan Inc.’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $3.07 billion and GAAP net loss of $120 million. In comparison, last year the company earned revenue of $2.7 billion and had a net profit of $429 million.

Mylan N.V., is a pharmaceutical company which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceutical products. It operates through two segments: Generic and Specialty. The Generic pharmaceutical business is conducted primarily in the U.S. and Canada; Europe; and India, Australia, Japan, New Zealand and Brazil as well as its export activity into emerging markets. The Specialty pharmaceutical business is conducted by Mylan Specialty L.P.. The company was founded on July 7, 2014 and is headquartered in Hatfield, United Kingdom.